Larimar Therapeutics (LRMR) Short-term Investments (2014 - 2025)

Larimar Therapeutics' Short-term Investments history runs 12 years deep, the most recent figure standing at $51.4 million for Q4 2025.

• Quarterly Short-term Investments fell 65.76% year-over-year to $51.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $51.4 million (down 65.76% YoY) and the FY2025 annual result came in at $51.4 million, down 65.76% from the prior year.
• Short-term Investments was $51.4 million for Q4 2025 at Larimar Therapeutics, down from $85.3 million in the prior quarter.
• Across five years, Short-term Investments topped out at $193.8 million in Q2 2024 and bottomed at $6.5 million in Q3 2021.
• A 5-year average of $83.7 million and a median of $72.7 million in 2023 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2023 — Short-term Investments slumped 71.93% — and 2024, when it surged 1861.26%.
• Larimar Therapeutics' Short-term Investments stood at $6.5 million in 2021, then soared by 1309.49% to $91.6 million in 2022, then sank by 34.46% to $60.0 million in 2023, then jumped by 150.22% to $150.2 million in 2024, then sank by 65.76% to $51.4 million in 2025.
• Business Quant data shows LRMR's Short-term Investments at $51.4 million in Q4 2025, $85.3 million in Q3 2025, and $117.9 million in Q2 2025.